Sirolimus in the treatment of kaposiform lymphangiomatosis

BACKGROUND: Kaposiform lymphangiomatosis (KLA), which is a new subtype of generalized lymphatic anomaly, is a rare disease with a poor prognosis. Currently, there is no standard treatment due to the poor understanding of KLA. Sirolimus, which is an inhibitor of mammalian target of rapamycin, has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiangyuan, Yang, Kaiying, Chen, Siyuan, Ji, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186093/
https://www.ncbi.nlm.nih.gov/pubmed/34103076
http://dx.doi.org/10.1186/s13023-021-01893-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186093/
https://www.ncbi.nlm.nih.gov/pubmed/34103076
http://dx.doi.org/10.1186/s13023-021-01893-3

Ejemplares similares